

REP G1=(0-10) CH
 ENTER (DIS), GRA, NOD, BON OR ?:end
 L7 STRUCTURE CREATED

=> search 17
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):13
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 15:06:18 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 792 TO ITERATE

100.0% PROCESSED 792 ITERATIONS 441 ANSWERS
 SEARCH TIME: 00.00.01

L8 441 SEA SUB=L3 SSS FUL L7

(FILE 'HOME' ENTERED AT 15:02:56 ON 01 SEP 2004)

FILE 'REGISTRY' ENTERED AT 15:03:03 ON 01 SEP 2004

L1 STRUC
L2 37 S L1
L3 792 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:04:32 ON 01 SEP 2004

L4 462 S L3
L5 298 S L4 AND PY<1998
L6 39 S L5 AND THU/RL

FILE 'REGISTRY' ENTERED AT 15:05:34 ON 01 SEP 2004

L7 STRUC
L8 441 SEARCH L7 SSS SUB=L3 FUL

FILE 'CAPLUS' ENTERED AT 15:06:22 ON 01 SEP 2004

L9 340 S L8
L10 215 S L9 AND PY<1998
L11 25 S L10 AND THU/RL

=> s l10 not l11
L12 190 L10 NOT L11

=> s l12 and p/dt
L13 4421885 P/DT
 35 L12 AND P/DT

=> s l8(l)thru/rl
L14 340 L8
 0 THRU/RL
 0 L8(L)THRU/RL


=> s l8(l)thu/rl
L15 340 L8
 616465 THU/RL
 42 L8(L)THU/RL

=> s l15 and py<1998
L16 18120816 PY<1998
 12 L15 AND PY<1998

=> d hitstr 12

L16 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
IT 82067-79-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antibacterial activity of)
RN 82067-79-6 CAPLUS
CN L-Proline, 1-[(4-(acetylamino)-3-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib hitstr 1-12

L16 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:568589 CAPLUS
 DN 129:175653
 TI Preparation of benzenesulfonamides as elastase inhibitors
 IN Nakae, Takahiko; Kato, Masashi; Fujita, Takehito; Kawabata, Kazuhito;
 Ohno, Hiroyuki
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO U.S., 150 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5795890	A	19980818	US 1996-718722	19960924
	JP 09165365	A2	19970624	JP 1995-272058	19950927 <--
	JP 09278742	A2	19971028	JP 1996-271341	19960924 <--
	JP 2881688	B2	19990412		
	JP 10251218	A2	19980922	JP 1998-111630	19960924
	AU 9665837	A1	19970410	AU 1996-65837	19960925 <--
	AU 714025	B2	19991216		
	ZA 9608069	A	19970520	ZA 1996-8069	19960925 <--
	NO 9604045	A	19970401	NO 1996-4045	19960926 <--
	CA 2186665	AA	19970328	CA 1996-2186665	19960927 <--
	AT 261960	E	20040415	AT 1996-307048	19960927
	US 5998410	A	19991207	US 1998-31192	19980226

PRAI JP 1995-272058 A 19950927
 JP 1996-45663 A 19960224
 JP 1996-271341 A3 19960924
 US 1996-718722 A3 19960924

OS MARPAT 129:175653

IT 190252-00-7P 190252-02-9P 190252-03-0P
 190252-13-2P 190252-15-4P 190252-17-6P
 190252-23-4P 190252-28-9P 190252-29-0P
 190252-30-3P 190252-31-4P 190252-32-5P
 190252-33-6P 190252-34-7P 190252-35-8P
 190253-22-6P 190253-23-7P 190253-25-9P
 190254-69-4P 190254-72-9P 190254-77-4P
 190254-82-1P 190254-92-3P 190255-06-2P
 190255-13-1P 190255-14-2P 211443-60-6P
 211486-47-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzenesulfonamides as elastase inhibitors)

RN 190252-00-7 CAPLUS

CN L-Proline, 1-[[3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190252-02-9 CAPLUS

CN L-Proline, 1-[[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190252-03-0 CAPLUS

CN D-Proline, 1-[[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190252-13-2 CAPLUS

CN L-Proline, 1-[(4-[(2-ethyl-2-(2-methoxyphenyl)-1-oxobutoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-15-4 CAPLUS

CN L-Proline, 1-[(4-[(2-ethyl-2-(2-methoxyphenyl)-1-oxobutoxy]phenyl)sulfonyl]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-17-6 CAPLUS

CN L-Proline, 1-[(4-[(2-ethyl-2-(2-methoxyphenyl)-1-oxobutoxy]phenyl)sulfonyl]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-23-4 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(4-methylphenyl)-1-oxobutoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-28-9 CAPLUS

CN L-Proline, 1-[(4-[(2-nitrophenyl)-1-oxobutoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-29-0 CAPLUS


CN L-Proline, 1-[(4-[(2R)-2-[(4-nitrophenyl)-1-oxobutoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-30-3 CAPLUS
 CN L-Proline, 1-[(4-[(2S)-2-(4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-31-4 CAPLUS
 CN L-Proline, 1-[(4-[(1-(4-nitrophenyl)cyclobutyl)carbonyl]oxy)phenyl]sulfonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-32-5 CAPLUS
 CN L-Proline, 1-[(3-methyl-4-[2-(4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-33-6 CAPLUS
 CN D-Proline, 1-[(4-[2-(4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-34-7 CAPLUS
 CN D-Proline, 1-[[4-[[1-(4-nitrophenyl)cyclobutyl]carbonyl]oxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190252-35-8 CAPLUS
 CN L-Proline, 1-[(4-(1-oxo-2-phenylbutoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190253-22-6 CAPLUS

CN 2H-1,4-Benzoxazine-6-acetic acid, α -ethyl-3,4-dihydro-3-oxo-, 4-[(2S)-2-carboxy-1-pyrrolidinyl]sulfonylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190253-23-7 CAPLUS

CN 2H-1,4-Benzoxazine-6-acetic acid, α -ethyl-3,4-dihydro-3-oxo-, 4-[(2R)-2-carboxy-1-pyrrolidinyl]sulfonylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190253-25-9 CAPLUS

CN 1H-Benzimidazole-5-acetic acid, α -ethyl-2-methyl-, 4-[(2S)-2-carboxy-1-pyrrolidinyl]sulfonylphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-69-4 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(2-methyl-4-oxobutoxy)phenyl]sulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-72-9 CAPLUS

CN L-Proline, 1-[(4-[(2-methoxy-4-oxobutoxy)phenyl]sulfonyl)-3-methylphenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 190254-77-4 CAPLUS
 CN L-Proline, 1-[[3-ethyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190254-82-1 CAPLUS
 CN L-Proline, 1-[[3-methyl-4-[2-(2-methyl-4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190254-92-3 CAPLUS
 CN L-Proline, 1-[[4-[2-(2-methoxy-4-nitrophenyl)-1-oxobutoxy]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190255-06-2 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-[(3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenoxy]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190255-13-1 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenoxy]phenyl]sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 190255-14-2 CAPLUS


CN L-Proline, 1-[(3-methyl-4-[(1-oxo-2-[(4-(1-pyrrolidinyl)phenyl]butoxy)phenyl]sulfonyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 190254-66-1

CMF C26 H32 N2 O6 S


Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 211443-60-6 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(1-oxo-2-[(3-(1-pyrrolidinyl)phenyl]butoxy)phenyl]sulfonyl)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 211486-47-4 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(1-oxo-2-[(4-(1-pyrrolidinyl)phenyl]-2-butenyl)oxy]phenyl]sulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



L16 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:805715 CAPLUS
DN 128:61793
TI Preparation of N-(phenylsulfonyl)amino acid derivatives as matrix metalloproteinase inhibitors
IN Takahashi, Kanji; Sugiura, Tsuneyuki
PA Ono Pharmaceutical Co., Ltd., Japan; Takahashi, Kanji; Sugiura, Tsuneyuki
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9745402	A1	19971204	WO 1997-JP1735	19970523 <--
	W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9727920	A1	19980105	AU 1997-27920	19970523
	JP 10265452	A2	19981006	JP 1997-148448	19970523
	EP 915086	A1	19990512	EP 1997-922148	19970523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI	JP 1996-151864		19960524		
	JP 1997-20879		19970121		
	WO 1997-JP1735		19970523		
OS	MARPAT 128:61793				
IT	200294-41-3P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-(phenylsulfonyl)amino acid derivs. as matrix metalloproteinase inhibitors for disease treatment)				
RN	200294-41-3 CAPLUS				
CN	D-Proline, 1-[[4-[(4-methylphenyl)ethynyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L16 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:390578 CAPLUS

DN 127:5005

TI Preparation of sulfamoylphenyl alkanoates as elastase inhibitors

IN Nakae, Takahiko; Kato, Masashi; Fujita, Takehito; Kawabata, Kazuhito; Ohno, Hiroyuki

PA Ono Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 270 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 769498	A1	19970423	EP 1996-307048	19960927 <--
	EP 769498	B1	20040317		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09165365	A2	19970624	JP 1995-272058	19950927 <--
	JP 09278742	A2	19971028	JP 1996-271341	19960924 <--
	JP 2881688	B2	19990412		
	JP 10251218	A2	19980922	JP 1998-111630	19960924
	AU 9665837	A1	19970410	AU 1996-65837	19960925 <--
	AU 714025	B2	19991216		
	ZA 9608069	A	19970520	ZA 1996-8069	19960925 <--
	NO 9604045	A	19970401	NO 1996-4045	19960926 <--
	CA 2186665	AA	19970328	CA 1996-2186665	19960927 <--
	AT 261960	E	20040415	AT 1996-307048	19960927
PRAI	JP 1995-272058	A	19950927		
	JP 1996-45663	A	19960224		
	JP 1996-271341	A3	19960924		
OS	MARPAT	127:5005			
IT	190252-00-7P	190252-02-9P	190252-03-0P		
	190252-13-2P	190252-15-4P	190252-17-6P		
	190252-23-4P	190252-28-9P	190252-29-0P		
	190252-30-3P	190252-31-4P	190252-32-5P		
	190252-33-6P	190252-34-7P	190252-35-8P		
	190253-22-6P	190253-23-7P	190253-25-9P		
	190254-57-0P	190254-58-1P	190254-59-2P		
	190254-60-5P	190254-66-1P	190254-69-4P		
	190254-72-9P	190254-77-4P	190254-82-1P		
	190254-89-8P	190254-92-3P	190255-06-2P		
	190255-13-1P	190255-14-2P	190255-84-6P		
	190255-85-7P	190256-41-8P	190256-42-9P		
	190256-43-0P	190256-44-1P	190256-50-9P		


190256-53-2P 190256-90-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of sulfamoylphenyl alkanoates as elastase inhibitors)

RN 190252-00-7 CAPLUS

CN L-Proline, 1-[[3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190252-02-9 CAPLUS

CN L-Proline, 1-[[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190252-03-0 CAPLUS

CN D-Proline, 1-[[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190252-13-2 CAPLUS

CN L-Proline, 1-[[4-[2-ethyl-2-(2-methoxyphenyl)-1-oxobutoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-15-4 CAPLUS

CN L-Proline, 1-[[4-[2-(2-methoxyphenyl)-1-oxobutoxy]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-17-6 CAPLUS

CN L-Proline, 1-[[4-[2-(4-methoxyphenyl)-1-oxobutoxy]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-23-4 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(4-methoxyphenyl)acetyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-28-9 CAPLUS

CN L-Proline, 1-[(4-[(4-nitrophenyl)acetyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-29-0 CAPLUS

CN L-Proline, 1-[(4-[(2R)-2-[(4-nitrophenyl)acetyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-30-3 CAPLUS

CN L-Proline, 1-[(4-[(2S)-2-(4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-31-4 CAPLUS

CN L-Proline, 1-[(4-[(1-(4-nitrophenyl)cyclobutyl)carbonyloxy]phenyl]sulfonyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190252-32-5 CAPLUS


CN L-Proline, 1-[(3-methyl-4-[2-(4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-33-6 CAPLUS
 CN D-Proline, 1-[(4-[(4-nitrophenyl)-1-oxobutoxy]phenyl]sulfonyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-34-7 CAPLUS
 CN D-Proline, 1-[(4-[(1-(4-nitrophenyl)cyclobutyl)carbonyloxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190252-35-8 CAPLUS
 CN L-Proline, 1-[(4-(1-oxo-2-phenylbutoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190253-22-6 CAPLUS

CN 2H-1,4-Benzoxazine-6-acetic acid, α -ethyl-3,4-dihydro-3-oxo-, 4-[(2S)-2-carboxy-1-pyrrolidinyl]sulfonylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190253-23-7 CAPLUS

CN 2H-1,4-Benzoxazine-6-acetic acid, α -ethyl-3,4-dihydro-3-oxo-, 4-[(2R)-2-carboxy-1-pyrrolidinyl]sulfonylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190253-25-9 CAPLUS

CN 1H-Benzimidazole-5-acetic acid, α -ethyl-2-methyl-, 4-[(2S)-2-carboxy-1-pyrrolidinyl]sulfonylphenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-57-0 CAPLUS

CN L-Proline, 1-[[3-methyl-4-[(2S)-1-oxo-2-[(4-(1-pyrrolidinyl)phenyl)butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-58-1 CAPLUS

CN D-Proline, 1-[[3-methyl-4-[(2S)-1-oxo-2-[(4-(1-pyrrolidinyl)phenyl)butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-59-2 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(2R)-1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-60-5 CAPLUS

CN D-Proline, 1-[(3-methyl-4-[(2R)-1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 190254-66-1 CAPLUS
CN L-Proline, 1-[(3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190254-69-4 CAPLUS
CN L-Proline, 1-[(3-methyl-4-[2-[2-methyl-4-(1-pyrrolidinyl)phenyl]-1-oxobutoxy]phenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 190254-72-9 CAPLUS

CN L-Proline, 1-[(4-[2-methoxy-4-(1-pyrrolidinyl)phenyl]-1-oxobutoxy)-3-methylphenyl]sulfonyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 190254-77-4 CAPLUS

CN L-Proline, 1-[(3-ethyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190254-82-1 CAPLUS


CN L-Proline, 1-[(3-methyl-4-[2-(2-methyl-4-nitrophenyl)-1-oxobutoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190254-89-8 CAPLUS
CN L-Proline, 1-[[3-methyl-4-[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]-2-butenyl]oxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 190254-92-3 CAPLUS
CN L-Proline, 1-[[4-[2-(2-methoxy-4-nitrophenyl)-1-oxobutoxy]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190255-06-2 CAPLUS
CN 2-Pyrrolidineacetic acid, 1-[[3-methyl-4-[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190255-13-1 CAPLUS

CN L-Proline, 1-[[3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 190255-14-2 CAPLUS


CN L-Proline, 1-[[3-methyl-4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 190254-66-1


CMF C26 H32 N2 O6 S

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 190255-84-6 CAPLUS
CN L-Proline, 1-[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl
]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190255-85-7 CAPLUS
CN D-Proline, 1-[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl
]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190256-41-8 CAPLUS
CN L-Proline, 1-[(3-methyl-4-[(2S)-1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190256-42-9 CAPLUS

CN D-Proline, 1-[(3-methyl-4-[(2S)-1-oxo-2-[4-(1-pyrrolidinyl)phenoxy]phenoxy]sulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190256-43-0 CAPLUS

CN L-Proline, 1-[(3-methyl-4-[(2R)-1-oxo-2-[4-(1-pyrrolidinyl)phenoxy]phenoxy]sulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190256-44-1 CAPLUS

CN D-Proline, 1-[(3-methyl-4-[(2R)-1-oxo-2-[4-(1-pyrrolidinyl)phenoxy]phenoxy]sulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190256-50-9 CAPLUS

CN L-Proline, 1-[[3-methyl-4-[2-[2-methyl-4-(1-pyrrolidinyl)phenyl]-1-oxobutoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190256-53-2 CAPLUS

CN L-Proline, 1-[[4-[2-methoxy-4-(1-pyrrolidinyl)phenyl]-1-oxobutoxy]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 190256-90-7 CAPLUS

CN 1H-Benzimidazole-5-acetic acid, α -ethyl-2-methyl-4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]phenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:251124 CAPLUS

DN 126:238316

TI Preparation of 3-(quinolylloxy)methylbenzenesulfonyl pyrrolidides and analogs as bradykinin antagonists

IN Dodey, Pierre; Bondoux, Michel; Houziaux, Patrick; Barth, Martine; Ou, Khan

PA Fournier Industrie Et Sante, Fr.; Dodey, Pierre; Bondoux, Michel; Houziaux, Patrick; Barth, Martine; Ou, Khan


SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9707115	A1	19970227	WO 1996-FR1262	19960807 <--
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2737892	A1	19970221	FR 1995-9885	19950817 <--
	FR 2737892	B1	19971024		
	EP 787131	A1	19970806	EP 1996-928492	19960807 <--
	EP 787131	B1	20011031		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10512285	T2	19981124	JP 1996-508988	19960807
	AT 207915	E	20011115	AT 1996-928492	19960807
	PT 787131	T	20020429	PT 1996-928492	19960807
	ES 2168501	T3	20020616	ES 1996-928492	19960807
	US 6080758	A	20000627	US 1997-817877	19970407
PRAI	FR 1995-9885	A	19950817		
	WO 1996-FR1262	W	19960807		
OS	MARPAT	126:238316			
IT	188440-06-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 3-(quinolylloxy)methylbenzenesulfonyl pyrrolidides and analogs as bradykinin antagonists)				
RN	188440-06-4	CAPLUS			
CN	Proline, 1-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl- (9CI) (CA INDEX NAME)				



L16 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:194733 CAPLUS

DN 124:261043

TI Preparation of sulfonylbenzyl-substituted imidazoles, imidazopyridines, and benzimidazoles for treatment of ocular disorders

IN Huebsch, Walter; Dressel, Juergen; Fey, Peter; Hanko, Rudolf; Kraemer, Thomas; Mueller, Ulrich; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav; et al.

PA Bayer A.-G., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4425950	A1	19960125	DE 1994-4425950	19940721 <--
PRAI	DE 1994-4425950			19940721	

OS MARPAT 124:261043


IT 162326-39-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of sulfonylbenzyl-substituted imidazoles, imidazopyridines, and benzimidazoles for treatment of ocular disorders)

RN 162326-39-8 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-butyl-1-[[4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-chlorophenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:494608 CAPLUS

DN 122:239708

TI Preparation of N-(sulfonylbenzyl)benzimidazoles as angiotensin II antagonists

IN Hanko, Rudolf; Kraemer, Thomas; Dressel, Juergen; Fey, Peter; Huebsch, Walter; Mueller, Ulrich; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav; et al.

PA Bayer A.-G., Germany

SO Ger. Offen., 20 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4327256	A1	19950216	DE 1993-4327256	19930813 <--
	EP 643060	A2	19950315	EP 1994-112023	19940802 <--
	EP 643060	A3	19950426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07053550	A2	19950228	JP 1994-206085	19940809 <--
	CA 2130020	AA	19950214	CA 1994-2130020	19940812 <--

PRAI DE 1993-4327256 19930813

OS CASREACT 122:239708; MARPAT 122:239708


IT 162326-38-7P 162326-39-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of N-(sulfonylbenzyl)benzimidazoles as angiotensin II antagonists)

RN 162326-38-7 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-butyl-1-[[4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-chlorophenyl]methyl]-, 7-methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162326-39-8 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-butyl-1-[[4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-chlorophenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 162326-41-2P 162326-42-3P 162326-43-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-(sulfonylbenzyl)benzimidazoles as angiotensin II antagonists)

RN 162326-41-2 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-butyl-1-[(4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-fluorophenyl)methyl]-, 7-methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162326-42-3 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-butyl-1-[(4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-fluorophenyl)methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162326-43-4 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-butyl-1-[(4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-chlorophenyl)methyl]-, dipotassium salt, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 K

L16 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:459523 CAPLUS

DN 122:214075

TI Preparation of substituted 2,4-imidazolidinedione arterial antihypertensive and antiatherosclerotic agents

IN Kraemer, Thomas; Hanko, Rudolf; Dressel, Juergen; Fey, Peter; Huebsch, Walter; Mueller, Ulrich E.; Mueller-Gliemann, Matthias; Bueck, Martin; Bischoff, Hilmar; et al.

PA Bayer A.-G., Germany

SO Eur. Pat. Appl., 30 pp.

CODEN: EPXXDW


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 626382	A1	19941130	EP 1994-107474	19940513 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	DE 4317321	A1	19941201	DE 1993-4317321	19930525 <--
	US 5530016	A	19960625	US 1994-245328	19940518 <--
	CA 2124057	AA	19941126	CA 1994-2124057	19940520 <--
	JP 06336478	A2	19941206	JP 1994-129917	19940520 <--
PRAI	DE 1993-4317321	A	19930525		
OS	MARPAT 122:214075				
IT	161913-22-0P 161913-23-1P 161913-24-2P 161913-25-3P 161913-26-4P 161913-27-5P 161913-28-6P 161913-29-7P 161913-30-0P 161913-31-1P 161913-32-2P 161972-75-4P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted 2,4-imidazolidinedione arterial antihypertensive and antiatherosclerotic agents)				
RN	161913-22-0	CAPLUS			
CN	Proline, 1-[(3-chloro-4-[(3-ethyl-2,4-dioxo-5-propyl-1-imidazolidinyl)methyl]phenyl)sulfonyl]-, (R*,S*)- (9CI) (CA INDEX NAME)				


Relative stereochemistry.



RN 161913-23-1 CAPLUS

CN L-Proline, 1-[[3-chloro-4-[(2,4-dioxo-3,5-dipropyl-1-imidazolidinyl)methyl]phenyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161913-24-2 CAPLUS

CN L-Proline, 1-[[4-[(3-butyl-2,4-dioxo-5-propyl-1-imidazolidinyl)methyl]-3-chlorophenyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161913-25-3 CAPLUS

CN 1-Imidazolidineacetic acid, 3-[[4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]-2-chlorophenyl)methyl]-2,5-dioxo-4-propyl-, α -ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161913-26-4 CAPLUS

CN L-Proline, 1-[(4-[(5-butyl-2,4-dioxo-3-propyl-1-imidazolidinyl)methyl]-3-chlorophenyl)sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161913-27-5 CAPLUS

CN L-Proline, 1-[(3-chloro-4-[(3,5-dibutyl-2,4-dioxo-1-imidazolidinyl)methyl]phenyl)sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 161913-28-6 CAPLUS

CN 1-Imidazolidineacetic acid, 4-butyl-3-[(4-[(2-carboxy-1-

pyrrolidinylsulfonyl]-2-chlorophenyl)methyl]-2,5-dioxo-, α -ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161913-29-7 CAPLUS

CN L-Proline, 1-[[3-chloro-4-[[3-ethyl-5-(1-methylethyl)-2,4-dioxo-1-imidazolidinyl]methyl]phenyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161913-30-0 CAPLUS

CN L-Proline, 1-[[3-chloro-4-[[5-(1-methylethyl)-2,4-dioxo-3-propyl-1-imidazolidinyl]methyl]phenyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 161913-31-1 CAPLUS

CN L-Proline, 1-[[4-[[3-butyl-5-(1-methylethyl)-2,4-dioxo-1-imidazolidinyl]methyl]-3-chlorophenyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 161913-32-2 CAPLUS

CN Proline, 1-[(3-chloro-4-[(3-ethyl-2,4-dioxo-5-propyl-1-imidazolidinyl)methyl]phenyl)sulfonyl]-, (R*,R*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 161972-75-4 CAPLUS

CN L-Proline, 1-[(3-chloro-4-[(3-ethyl-2,4-dioxo-5-propyl-1-imidazolidinyl)methyl]phenyl)sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:217310 CAPLUS

DN 120:217310

TI Preparation of N-(sulfonylbenzyl)benzo- and -pyridopyridones as angiotensin II antagonists
IN Dressel, Juergen; Fey, Peter; Hanko, Rudolf H.; Huebsch, Walter; Kraemer, Thomas; Mueller, Ulrich E.; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav; et al.


PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 569795	A1	19931118	EP 1993-106988	19930429 <--
	EP 569795	B1	19950412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE DE 4215587	A1	19931118	DE 1992-4215587	19920512 <--
	AU 9337106	A1	19931118	AU 1993-37106	19930422 <--
	NO 9301534	A	19931115	NO 1993-1534	19930427 <--
	AT 121086	E	19950415	AT 1993-106988	19930429 <--
	ES 2072784	T3	19950716	ES 1993-106988	19930429 <--
	US 5354749	A	19941011	US 1993-58548	19930505 <--
	JP 06049031	A2	19940222	JP 1993-127805	19930506 <--
	CA 2095801	AA	19931113	CA 1993-2095801	19930507 <--
	ZA 9303273	A	19931129	ZA 1993-3273	19930511 <--
	CN 1080923	A	19940119	CN 1993-105760	19930512 <--
PRAI	DE 1992-4215587		19920512		
OS	MARPAT 120:217310				
IT	153801-98-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)				
RN	153801-98-0 CAPLUS				
CN	L-Proline, 1-[[4-[(3-butyl-1-oxo-2(1H)-isoquinolinyl)methyl]-3-chlorophenyl]sulfonyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L16 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:107008 CAPLUS

DN 120:107008


TI Preparation of sulfonylbenzylimidazoles as angiotensin II antagonists

IN Hanko, Rudolf; Dressel, Juergen; Fey, Peter; Huebsch, Walter; Kraemer,

Thomas; Mueller, Ulrich; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav; et al.
 PA Bayer A.-G., Germany
 SO Ger. Offen., 19 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4206043 EP 562261 EP 562261	A1 A2 A3	19930902 19930929 19940413	DE 1992-4206043 EP 1993-102324	19920227 <-- 19930215 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE US 5318980 CA 2090274 AU 9333771 ZA 9301369 HU 64332 JP 06041087 CN 1077710	DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE A AA A1 A A2 A2 A	19940607 19930828 19930902 19930924 19931228 19940215 19931027	US 1993-18961 CA 1993-2090274 AU 1993-33771 ZA 1993-1369 HU 1993-540 JP 1993-61347 CN 1993-102461	19930218 <-- 19930224 <-- 19930224 <-- 19930226 <-- 19930226 <-- 19930226 <-- 19930227 <--
PRAI	DE 1992-4206043		19920227		
OS	MARPAT 120:107008				
IT	152297-14-8P			RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use) ; BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)	
RN	152297-14-8 CAPLUS				
CN	1H-Imidazole-5-carboxylic acid, 2-butyl-1-[[4-[(2-carboxy-1-pyrrolidinyl)sulfonyl]phenyl]methyl]-4-chloro-, (S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




L16 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:107007 CAPLUS
 DN 120:107007
 TI Preparation of sulfonylbenzyl-substituted imidazopyridines as angiotensin II antagonists
 IN Hanko, Rudolf; Dressel, Juergen; Fey, Peter; Huebsch, Walter; Kraemer, Thomas; Mueller, Ulrich; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav; et al.
 PA Bayer A.-G., Germany
 SO Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


PI	DE 4206042	A1	19930902	DE 1992-4206042	19920227 <--
	EP 564788	A2	19931013	EP 1993-102325	19930215 <--
	EP 564788	A3	19931020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5364942	A	19941115	US 1993-18964	19930218 <--
	CA 2090279	AA	19930828	CA 1993-2090279	19930224 <--
	AU 9333772	A1	19930902	AU 1993-33772	19930224 <--
	JP 06049068	A2	19940222	JP 1993-61077	19930225 <--
	HU 64341	A2	19931228	HU 1993-543	19930226 <--
	CN 1077195	A	19931013	CN 1993-102154	19930227 <--
PRAI	DE 1992-4206042		19920227		
OS	MARPAT 120:107007				
IT	152531-04-9P 152531-07-2P 152531-14-1P 152531-15-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as angiotensin II antagonist)				
RN	152531-04-9 CAPLUS				
CN	L-Proline, 1-[(4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-3-chlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 152531-07-2 CAPLUS
 CN L-Proline, 1-[(4-[(2-butyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152531-14-1 CAPLUS
 CN L-Proline, 1-[(4-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152531-15-2 CAPLUS
 CN L-Proline, 1-[(3-chloro-4-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 11 OF 12 CAPLUS. COPYRIGHT 2004 ACS on STN
 AN 1990:514810 CAPLUS
 DN 113:114810
 TI Preparation of p-substituted phenyl ester of pivalic acid as elastase inhibitors and pharmaceutical compositions
 IN Imaki, Katsuhiro; Arai, Yoshinobu; Okegawa, Tadao
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 91 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 347168	A1	19891220	EP 1989-305959	19890613 <--
EP 347168	B1	19930901		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5017610	A	19910521	US 1989-364994	19890612 <--
CA 1340191	A1	19981215	CA 1989-602530	19890612
JP 03020253	A2	19910129	JP 1989-148479	19890613 <--
JP 05081586	B4	19931115		
AT 93843	E	19930915	AT 1989-305959	19890613 <--
ES 2059752	T3	19941116	ES 1989-305959	19890613 <--
JP 06179645	A2	19940628	JP 1992-241380	19920819 <--
JP 06094450	B4	19941124		
US 5336681	A	19940809	US 1992-960301	19921013 <--

PRAI US 5403850 A 19950404 US 1994-235856 19940429 <--
 JP 1988-145450 19880613
 JP 1989-53541 19890306
 US 1989-364994 19890612
 EP 1989-305959 19890613
 US 1991-681364 19910408
 US 1992-960301 19921013
 OS MARPAT 113:114810
 IT 127373-23-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as elastase inhibitor)
 RN 127373-23-3 CAPLUS
 CN L-Proline, 1-[(4-(2,2-dimethyl-1-oxopropoxy)-3-methylphenyl)sulfonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:457157 CAPLUS
 DN 111:57157
 TI Synthesis of biologically active 4-acetylaminophenylsulfonic acid derivatives. Part I
 AU Aly, F. M.; Bedair, A. A.; Haddad, A. F.; Hassan, M. F. A.
 CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt
 SO Egyptian Journal of Pharmaceutical Sciences (1988), 29(1-4), 111-19
 CODEN: EJPSBZ; ISSN: 0301-5068
 DT Journal
 LA English
 OS CASREACT 111:57157
 IT 82067-79-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antibacterial activity of)
 RN 82067-79-6 CAPLUS
 CN L-Proline, 1-[(4-(acetylaminophenyl)sulfonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

